3-(5-Methyl-1,2,4-oxadiazol-3-yl)-8-azabicyclo[3.2.1]octane hydrochloride

Catalog No.: 
ACFACT085
CAS No.: 
2060005-01-6
Molecular Formula: 
C10H16ClN3O
Molecular Weight: 
229.71
3-(5-Methyl-1,2,4-oxadiazol-3-yl)-8-azabicyclo[3.2.1]octane hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$281.00InquiryInquiry
100mg95%$410.00InquiryInquiry
250mg95%$899.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(5-Methyl-1,2,4-oxadiazol-3-yl)-8-azabicyclo[3.2.1]octane hydrochloride
IUPAC Name3-(8-azabicyclo[3.2.1]octan-3-yl)-5-methyl-1,2,4-oxadiazole hydrochloride
MDL No.MFCD29046362
Molecular FormulaC10H16ClN3O
Molecular Weight229.71
SMILESCC1=NC(C2CC(N3)CCC3C2)=NO1.[H]Cl
InChI KeyDVQGRPJEVNJPDP-UHFFFAOYSA-N
Synonym3-(8-Azabicyclo[3.2.1]octan-3-yl)-5-methyl-1,2,4-oxadiazole Hydrochloride;3-(5-Methyl-1,2,4-oxadiazol-3-yl)-8-azabicyclo[3.2.1]octane hydrochloride
CAS No.2060005-01-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACFACT085 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFACT085 route product structure diagram
    ACFACT0852060005-01-6
Inquiry

2. ACFACT085 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFACT085 route product structure diagram
    ACFACT0852060005-01-6
Inquiry

3. ACFACT085 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFACT085 route product structure diagram
    ACFACT0852060005-01-6
Inquiry

Comments (0)